Literature DB >> 10430083

Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhood.

M Bredel1, I F Pollack, R L Hamilton, C D James.   

Abstract

Epidermal growth factor receptor (EGFR) is commonly overexpressed in adult high-grade gliomas. Forty to 50% of such tumors demonstrate amplification of the EGFR gene, often with rearrangement and constitutive activation of the gene product, suggesting that EGFR might play a role in the malignant progression of a subset of these neoplasms. In this regard, several groups have shown that overexpression of EGFR is associated with an adverse outcome in adult gliomas. In contrast to the extensive studies of EGFR status that have been performed in adult high-grade gliomas, little information has been reported about EGFR expression and amplification, as well as their prognostic relevance in high-grade gliomas of childhood, which carry a somewhat more favorable prognosis than their adult counterparts. To address this issue, we examined the expression of EGFR using immunohistochemistry and screened for amplification of the EGFR gene using a competitive PCR in a series of 27 archival pediatric high-grade nonbrainstem gliomas treated consecutively at our institution between 1975 and 1992. Tumors were categorized based on protein expression patterns, and the association between expression status and outcome was examined. Although elevated immunoreactivity for EGFR was observed in 80% of tumors, only two of the cases had gene amplification. No difference in outcome was observed between tumors that exhibited extensive EGFR immunoreactivity and those that did not (P > 0.3). Although EGFR expression did not seem to be of prognostic relevance for the outcome of pediatric patients harboring high-grade nonbrainstem gliomas, the consistently high levels of expression of EGFR in these neoplasms suggest that this receptor plays a role in the malignant phenotype of these tumors. Accordingly, treatment approaches targeting EGFR might be of potential therapeutic benefit for high-grade gliomas of childhood.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10430083

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  69 in total

1.  Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas: a report from the Children's Oncology Group.

Authors:  Ian F Pollack; Ronald L Hamilton; Robert W Sobol; Marina N Nikiforova; Yuri E Nikiforov; Maureen A Lyons-Weiler; William A LaFramboise; Peter C Burger; Daniel J Brat; Marc K Rosenblum; Floyd H Gilles; Allan J Yates; Tianni Zhou; Kenneth J Cohen; Jonathan L Finlay; Regina I Jakacki
Journal:  Pediatr Blood Cancer       Date:  2010-12-01       Impact factor: 3.167

2.  IDH1 mutations are common in malignant gliomas arising in adolescents: a report from the Children's Oncology Group.

Authors:  Ian F Pollack; Ronald L Hamilton; Robert W Sobol; Marina N Nikiforova; Maureen A Lyons-Weiler; William A LaFramboise; Peter C Burger; Daniel J Brat; Marc K Rosenblum; Emiko J Holmes; Tianni Zhou; Regina I Jakacki
Journal:  Childs Nerv Syst       Date:  2010-08-20       Impact factor: 1.475

3.  Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors.

Authors:  Birgit Geoerger; Darren Hargrave; Fabienne Thomas; Anna Ndiaye; Didier Frappaz; Felipe Andreiuolo; Pascale Varlet; Isabelle Aerts; Riccardo Riccardi; Timothy Jaspan; Etienne Chatelut; Marie-Cecile Le Deley; Xavier Paoletti; Christian Saint-Rose; Pierre Leblond; Bruce Morland; Jean-Claude Gentet; Valérie Méresse; Gilles Vassal
Journal:  Neuro Oncol       Date:  2010-10-25       Impact factor: 12.300

4.  Evaluation of patritumab with or without erlotinib in combination with standard cytotoxic agents against pediatric sarcoma xenograft models.

Authors:  Abhik Bandyopadhyay; Edward Favours; Doris A Phelps; Vanessa Del Pozo; Samson Ghilu; Dias Kurmashev; Joel Michalek; Aron Trevino; Denis Guttridge; Cheryl London; Kenji Hirotani; Ling Zhang; Raushan T Kurmasheva; Peter J Houghton
Journal:  Pediatr Blood Cancer       Date:  2017-10-28       Impact factor: 3.167

Review 5.  Molecular analysis of pediatric brain tumors.

Authors:  Jaclyn A Biegel; Ian F Pollack
Journal:  Curr Oncol Rep       Date:  2004-11       Impact factor: 5.075

6.  IGFBP2 is overexpressed by pediatric malignant astrocytomas and induces the repair enzyme DNA-PK.

Authors:  Oren J Becher; Katia M Peterson; Soumen Khatua; Maria R Santi; Tobey J MacDonald
Journal:  J Child Neurol       Date:  2008-10       Impact factor: 1.987

7.  Molecular genetic changes in a series of neuroepithelial tumors of childhood.

Authors:  Alessia Di Sapio; Isabella Morra; Luca Pradotto; Marilena Guido; Davide Schiffer; Alessandro Mauro
Journal:  J Neurooncol       Date:  2002-09       Impact factor: 4.130

8.  Phase I and pharmacokinetic studies of erlotinib administered concurrently with radiotherapy for children, adolescents, and young adults with high-grade glioma.

Authors:  Alberto Broniscer; Suzanne J Baker; Clinton F Stewart; Thomas E Merchant; Fred H Laningham; Paula Schaiquevich; Mehmet Kocak; E Brannon Morris; Raelene Endersby; David W Ellison; Amar Gajjar
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

9.  Cytogenetic analysis of paediatric astrocytoma using comparative genomic hybridisation and fluorescence in-situ hybridisation.

Authors:  Samantha J Ward; Katherine Karakoula; Kim P Phipps; William Harkness; Richard Hayward; Dominic Thompson; Thomas S Jacques; Brian Harding; John L Darling; David G T Thomas; Tracy J Warr
Journal:  J Neurooncol       Date:  2010-01-06       Impact factor: 4.130

10.  Nimotuzumab prolongs survival in patients with malignant gliomas: A phase I/II clinical study of concomitant radiochemotherapy with or without nimotuzumab.

Authors:  Jidong Hong; Yuping Peng; Yuping Liao; Wuzhong Jiang; Rui Wei; Lei Huo; Zaide Han; Chaojun Duan; Meizuo Zhong
Journal:  Exp Ther Med       Date:  2012-04-19       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.